Clinical Pathways

Patient-Centered Clinical Pathways Should Incorporate the Patient’s Voice

Chase Doyle

October 2019, Vol 10, No 5 - Clinical Pathways

San Diego, CA—Patient-centered clinical pathways may hold the promise of truly personalized medicine, improving value-based care and clinical outcomes. However, according to Cary P. Gross, MD, Director, Cancer Outcomes, Public Policy and Effectiveness Research Center, Yale School of Medicine, New Haven, CT, substantial challenges still stand in the way of including the patient’s voice in these pathways. [ Read More ]

Clinical Pathways Help Integrate New Drugs, Reduce Variability in Care Delivery

Charles Bankhead

December 2017, Vol 8, No 5 - Clinical Pathways

Chicago, IL—Clinical pathways have an important role in the integration of new cancer drugs into clinical practice. Between January 2015 and mid-2017, the FDA granted more than 60 new approvals in oncology, with new drugs accounting for the vast majority (as opposed to new indications). Staying abreast of new drugs and new indications for specific types of cancer requires much time, which presents an extra burden on community oncologists. [ Read More ]

Clinical Pathways in Payment Reform Should Address Risk Adjustment

Chase Doyle

September 2016, Vol 7, No 8 - Clinical Pathways

It does not take a crystal ball, or even an economist, to foretell that disaster is imminent in the healthcare system if premiums and out-of-pocket costs continue to rise, along with the cost of cancer drugs. Although the government attempts to rectify the situation with Medicare payment reform, new payment and care delivery models, such as the Oncology Care Model (OCM) pilot, and laws, such as the 2015 Medicare Access and CHIP Reauthorization Act (MACRA), present financial challenges for oncologists. [ Read More ]